Drugs / DM002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06751329 | Feb 2025 → Oct 2027 expected | carcinoma, colorectal neoplasm, endometrium neoplasm, malignant pancreatic neoplasm +2 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06751329 ↗ |
| Modality | Other / unclassified | “DM002, a bispecific antibody-drug conjugate (ADC) developed using fully human antibodies with a common light chain, which targets MUC1 and HER3.” NCT06751329 ↗ |
| Route | Intravenous | “for intravenous (IV) infusion” NCT06751329 ↗ |
| Target | MUC1 | “DM002, a bispecific antibody-drug conjugate (ADC) developed using fully human antibodies with a common light chain, which targets MUC1 and HER3.” NCT06751329 ↗ |